Sermorelin is having a moment.

Jake and Cynthia unpack the growth hormone peptide everyone's pivoting to: what it is (a copy of your body's own GHRH signal), how it works (pulsatile, feedback-intact), what the research actually shows (nocturnal GH up, lean mass up in men, skin thickness up in both sexes), and why it's trending now that ipamorelin is restricted. Plus its surprising pedigree: an FDA-approved drug (Geref, 1997) that left the market for business reasons, not safety. Honest bottom line included.

Also: the weekly GLP pulse — Retatrutide goes mainstream, CagriSema food-noise data, and a $2.6B oral GLP-1 deal.

For research and informational purposes only — not medical advice.

Sources:

• Prime Lab Peptides — sermorelin pituitary signaling (Khorram 1997): https://primelabpeptides.com/blogs/news/how-does-sermorelin-influence-pituitary-signaling-pathways-in-endocrine-research

• Sermorelin myths vs. reality (Geref 1997/2008, 503A compounding): https://medium.com/@esochabiakasikhi/sermorelin-peptide-myths-vs-reality-bdeea758b588

• Scientific American — growth hormone peptides and the evidence: https://www.scientificamerican.com/article/growth-hormone-peptides-promise-to-stall-aging-but-does-the-science-stack-up/

• The BMJ — retatrutide TRIUMPH Phase 3: http://www.bmj.com/content/395/bmj-2026-101016

• Pharmacy Times — CagriSema curbs food noise: https://www.pharmacytimes.com/view/cagrisema-curbs-food-noise-organ-fat-in-patients-with-obesity-t2d-respectively

• Business News Today — Novo–Hengrui $2.6B deal: https://business-news-today.com/hengrui-lands-2-6bn-novo-nordisk-deal-for-experimental-weekly-oral-obesity-drug/